Xeltis Secures €50 Million to Advance Hemodialysis Innovation
Utrecht, Tuesday, 2 December 2025.
Xeltis receives nearly €50 million from Invest-NL, EIB, and investors to commercialize aXess, a vascular access device for hemodialysis, marking a significant step in medtech innovation.
Innovative Medtech Device for Hemodialysis
Xeltis, a pioneering medtech company based in the Netherlands, has secured a significant investment round amounting to nearly €50 million. This funding comes from Invest-NL, the European Investment Bank (EIB), and existing investors such as EQT. The investment aims to advance the development and commercialization of Xeltis’ innovative vascular access device known as aXess, which is designed specifically for hemodialysis patients [1][2].
The Promise of aXess
The aXess device represents a breakthrough in medical technology, utilizing natural tissue restoration to improve the quality of life for patients undergoing hemodialysis. Traditional vascular access methods often fail or lead to complications, but aXess is engineered to reduce infection rates and the need for interventions, as shown in recent clinical trials [1][3]. This innovation is expected to set a new standard in patient care by providing more sustainable and less invasive treatment options [1].
Strategic Steps Towards Commercialization
With the newly secured funding, Xeltis is poised to take significant steps towards the commercial introduction of aXess. The company plans to upscale production, expand its workforce, and prepare for market approvals in Europe and the United States by 2026. This strategic move underscores the company’s commitment to bringing their life-changing technology to patients worldwide [1][3].
Collaborative Efforts in Medtech Advancement
The investment in Xeltis highlights the importance of collaborative efforts between public and private sectors in advancing healthcare technologies. Invest-NL, along with the EIB and other stakeholders, plays a crucial role in supporting startups that drive innovation in the medtech field [1][2]. This initiative not only boosts the Dutch medtech industry but also sets a precedent for similar ventures aimed at improving healthcare outcomes globally [1][4].